聯康生物科技集團(00690.HK)與寶萃訂立研發合作協議
格隆匯1月4日丨聯康生物科技集團(00690.HK)發佈公吿,2022年1月4日,公司間接全資附屬公司Uni-Bioscience Pharm與寶萃就該項目訂立研發合作協議,以共同開發用於醫療美容用途的新項目材料。
該項目下的新項目材料包括膠原蛋白等產品。Uni-Bioscience Pharm及寶萃須共同開發新項目材料,包括新項目材料的研發、生產、分銷及銷售。該項目下的新項目材料將用於醫學美容用途,且預計將供應予化粧品公司、化粧品代工公司及可能需要有關新材料的其他公司。根據研發合作協議,該項目可能產生或衍生的知識產權須由Uni-Bioscience Pharm及寶萃共同擁有。
公吿稱,集團擁有一個強大的重組蛋白及多肽開發平台,能夠高效地開發及交付用於多種應用的高價值、以性能為導向的原料。寶萃為一間化粧品原料開發公司,在化粧品原料的開發方面具有豐富的經驗。雙方將共同開發具有競爭優勢(技術及成本優勢)的用於醫學美容用途的新項目材料。倘該項目下的新項目材料將達到實際分銷及銷售的階段,公司將於新項目材料的分銷及銷售實現時遵守與新項目材料的分銷及銷售項下擬進行交易有關的相關上市規則的要求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.